Thus, preventing the biosynthesis of miR-22-3p or inhibiting the activation of its target gene, ACSL4, shows promise as a novel therapeutic strategy for neutralizing the impact of CVD on tumor progression by halting the exosome-mediated pathological communication between MI and tumor tissue (197) (Figure 6). The gene discussed is ACSL4; the disease is neoplasm.